# OnCo record lung-map (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/lung-map/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "lung-map", "NCT02154490" ;
  schema:name "Lung-MAP (SWOG S1400 and S1900)"@en ;
  schema:alternateName "Lung Master Protocol"@en, "LUNGMAP"@en, "Lung-MAP S1400"@en, "S1400"@en, "S1900"@en ;
  schema:description "Lung-MAP is the United States public-private umbrella trial in lung cancer: every patient gets one genomic test and is sent to whichever experimental drug matches their tumour, with the rest joining immunotherapy arms. Its first matched drugs disappointed; its immunotherapy combinations produced the platform's first survival signal."@en ;
  schema:url <https://onco.cc/trials/lung-map/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02154490>, <https://clinicaltrials.gov/study/NCT03851445>, <https://doi.org/10.1158/1078-0432.CCR-13-3473>, <https://doi.org/10.1016/S1470-2045(20)30475-7>, <https://doi.org/10.1016/j.jtho.2024.07.024> ;
  onco:status "completed" ;
  onco:phase "platform" ;
  schema:startDate "2014-07-08" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cdk46-inhibitor/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/telisotuzumab-vedotin/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/erlotinib/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/foundation-medicine/>, <https://onco.cc/companies/swog/>, <https://onco.cc/companies/ecog-acrin/>, <https://onco.cc/companies/alliance-oncology/>, <https://onco.cc/companies/nrg-oncology/> ;
  onco:institutions <https://onco.cc/institutions/nci/> ;
  onco:terms <https://onco.cc/terms/master-protocol/>, <https://onco.cc/terms/seamless-adaptive/>, <https://onco.cc/terms/basket-umbrella-platform/> ;
  onco:trials <https://onco.cc/trials/lung-map-s1400i/>, <https://onco.cc/trials/lung-map-s1800a/> ;
  onco:people <https://onco.cc/people/roy-herbst/>, <https://onco.cc/people/karen-kelly/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-kozono-j-thorac-oncol/>, <https://onco.cc/key-papers/paper-redman-lancet-oncol/>, <https://onco.cc/key-papers/paper-herbst-clin-cancer-res/>, <https://onco.cc/key-papers/paper-lung-map-j-thorac-oncol-2019/> .